Drug Profile
Arzoxifene
Alternative Names: Arzoxifene hydrochloride; LY353381; SERM III; SERM-3Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Osteoporosis therapies; Piperidines; Thiophenes
- Mechanism of Action Selective estrogen receptor agonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer; Postmenopausal osteoporosis
Most Recent Events
- 15 Sep 2009 Efficacy data from a phase III trial in postmenopausal osteoporosis presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
- 25 Mar 2009 Efficacy and safety data from the phase III, NEXT trial in Postmenopausal osteoporosis released by Eli Lilly
- 11 Dec 2007 Clinical development is ongoing